Entering text into the input field will update the search result below

AstraZeneca, Daiichi Sankyo's Enhertu gets FDA breakthrough therapy tag for breast cancer subtype

Breast cancer awareness ribbon with leaves decoration background, copy space text, 3d rendering illustration

sofirinaja/iStock via Getty Images

  • The Food and Drug Administration (FDA) granted breakthrough therapy designation to AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer.
  • The FDA status for Enhertu is to treat adult patients with unresectable

Recommended For You

Related Stocks

SymbolLast Price% Chg
AZN
--
DSNKY
--